No services found
No Products found
100ug
ProteoGenix
Primary Antibodies
Monoclonal Antibody
Mammalian cells
Elisa, WB
Cilgavimab is a monoclonal antibody targeting spike protein of SARS-CoV-2. This humanized biosimilar belong to the family of immunoglobulin G1- type. Cilgavimab has been recently approved by FDA and EMA to be used in emergency as prophylactic treatment against COVID-19 in association with Tixagevimab.
The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
Cilgavimab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use
Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Each of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic.
Publication
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? * WB ELISA Sandwich ELISA IF IHC IP FC other
Did it work in your application? * Yes No
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Related products
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.